Literature DB >> 26459547

Delamanid and QT prolongation in the treatment of multidrug-resistant tuberculosis.

Rajesh Gupta1, Lawrence J Geiter2, Jeffrey Hafkin2, Charles D Wells2.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26459547     DOI： 10.5588/ijtld.15.0541

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN： 1027-3719            Impact factor:   2.373


× No keyword cloud information.
  4 in total

1.  QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.

Authors:  Kelly E Dooley; Susan L Rosenkranz; Francesca Conradie; Laura Moran; Richard Hafner; Florian von Groote-Bidlingmaier; Javier R Lama; Justin Shenje; Jorge De Los Rios; Kyla Comins; Joel Morganroth; Andreas H Diacon; Yoninah S Cramer; Kathleen Donahue; Gary Maartens
Journal:  Lancet Infect Dis       Date:  2021-02-12       Impact factor: 71.421

2.  Prediction of potential drug interactions between repurposed COVID-19 and antitubercular drugs: an integrational approach of drug information software and computational techniques data.

Authors:  Levin Thomas; Sumit Raosaheb Birangal; Rajdeep Ray; Sonal Sekhar Miraj; Murali Munisamy; Muralidhar Varma; Chidananda Sanju S V; Mithu Banerjee; Gautham G Shenoy; Mahadev Rao
Journal:  Ther Adv Drug Saf       Date:  2021-08-26

3.  Population Pharmacokinetic and Concentration-QTc Analysis of Delamanid in Pediatric Participants with Multidrug-Resistant Tuberculosis.

Authors:  Tomohiro Sasaki; Elin M Svensson; Xiaofeng Wang; Yanlin Wang; Jeffrey Hafkin; Mats O Karlsson; Suresh Mallikaarjun
Journal:  Antimicrob Agents Chemother       Date:  2021-11-29       Impact factor: 5.191

4.  Preparedness of outpatient health facilities for ambulatory treatment with all-oral short DR-TB treatment regimens in Zhytomyr, Ukraine: a cross-sectional study.

Authors:  Tinne Gils; Chinmay Laxmeshwar; Marve Duka; Khachatur Malakyan; Olga Valentinovna Siomak; Vitaly Stephanovich Didik; Natalia Lytvynenko; Yana Terleeva; Dmytri Donchuk; Petros Isaakidis
Journal:  BMC Health Serv Res       Date:  2020-09-21       Impact factor: 2.655
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.